GLP-1 Receptor Agonists Linked to Reduced CRC Risk in Type 2 Diabetes Patients
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer a significant protective benefit against colorectal cancer (CRC), according to findings from a global database analysis presented at DDW 2025.
In a large retrospective cohort study using the TriNetX platform, researchers evaluated the 10-year risk of developing CRC among adults aged 18 to 90 with type 2 diabetes mellitus (T2DM) who were treated either with GLP-1RAs or other oral antidiabetic agents. After matching, each treatment group included 152,318 patients. Those on GLP-1RAs had a notably lower risk of CRC compared to those on medications such as thiazolidinediones, sulfonylureas, SGLT2 inhibitors, and DPP-4 inhibitors (hazard ratio [HR]: 0.648; 95% CI: 0.539–0.780).
Interestingly, GLP-1RA users also had higher reported rates of constipation (HR: 1.375) and hemorrhoids (HR: 1.359), symptoms that may have prompted increased screening. Indeed, these patients underwent more colonoscopies (HR: 1.347) than those in the comparison group, raising the possibility that earlier cancer detection played a role in the observed reduction in CRC risk.
Importantly, no significant differences were found between the cohorts in the incidence of other gastrointestinal malignancies, including cancers of the esophagus, stomach, or small intestine, suggesting a potential CRC-specific effect.
These results highlight the possible dual impact of GLP-1RAs in not only managing metabolic disease but also reducing colorectal cancer risk through both biological mechanisms and increased diagnostic vigilance.
